YOLFTbeta
SK Bioscience Co Ltd

SK Bioscience Co Ltd

302440 · KO · Healthcare / Biotechnology

39,000.00KRW-450.00 (-1.14%)

Price History

Full chart

Market Stats

Previous Close39,450.00
Open38,800.00
Day Range38,800.00 – 40,050.00
52-Week Range31,800.00 – 61,300.00
Volume65.09K
Market Cap2.89T
P/E (TTM)0.00
Forward P/E46.51
Dividend Yield0.00%
Beta0.88
50-Day Avg36,295.00
200-Day Avg42,066.00

About

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jae-Yong Ahn
  • Employees917
  • Headquarters310, Pangyo-ro, Seongnam-si, South Korea, 13494, Korea
  • Websitehttps://www.skbioscience.co.kr

Leadership

  • Mr. Jae-Yong AhnCEO, President & Director · b. 1967
  • Dr. Sally ChoeHead of Global Clinical Development & Regulatory Affairs
  • Ki-seok SongValue Innovation Director · b. 1970
  • Jin-seon ParkHead of Marketing & Business Development · b. 1973
  • Jung-seok LeeRegistered Executive

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue88.17B183.94B225.61B929.00B456.73B369.51B267.55B651.37B
Growth (%)-+108.61%+22.66%+311.77%-50.84%-19.10%-27.59%+143.46%
Cost of Revenue48.96B110.90B130.27B358.72B217.11B227.26B236.57B575.44B
Gross Profit39.22B79.64B95.34B570.28B239.61B142.24B30.98B75.92B
Gross Margin44.48%43.30%42.26%61.39%52.46%38.50%11.58%11.66%
Operating Expense24.01B73.17B57.63B96.06B124.60B154.23B169.41B199.43B
Operating Income15.21B6.47B37.71B474.22B115.01B-11.99B-138.43B-123.50B
Operating Margin17.25%3.52%16.71%51.05%25.18%-3.24%-51.74%-18.96%
EBITDA9.88B37.21B57.97B493.33B171.43B43.49B-36.20B14.55B
EBITDA Margin11.20%20.23%25.70%53.10%37.53%11.77%-13.53%2.23%
Net Income420.84M14.68B32.89B355.14B122.45B22.32B-53.88B-57.42B
Net Income Margin0.48%7.98%14.58%38.23%26.81%6.04%-20.14%-8.82%
R&D10.51B27.72B25.99B47.25B57.96B85.74B71.35B69.86B
R&D as % of Total Revenue11.92%15.07%11.52%5.09%12.69%23.20%26.67%10.73%
Interest Expense2.42B3.95B4.15B3.43B2.46B1.40B3.68B9.40B
Interest Expense % of Total Revenue2.75%2.15%1.84%0.37%0.54%0.38%1.38%1.44%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets402.71B403.98B562.23B2.11T2.14T1.85T2.84T2.96T
Total Liabilities191.98B171.25B298.44B508.81B400.23B148.58B821.14B918.29B
Total Equity210.73B232.73B263.79B1.60T1.74T1.70T1.80T1.79T
Cash4.49B14.38B24.97B98.03B225.29B127.03B312.70B105.55B
Net Debt132.57B102.25B88.26B---70.63B359.19B

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow14.90B21.82B120.22B536.59B-124.96B29.35B-128.02B102.51B
Investing Cash Flow---108.09B-1.42T----
Financing Cash Flow---1.54B958.38B----
Capital Expenditure6.31B23.97B9.93B42.91B76.49B50.30B172.22B260.38B
Free Cash Flow8.59B-4.04B110.03B492.12B-201.45B-20.95B-300.24B-157.87B
FCF to OCF57.66%-18.50%91.52%91.71%161.21%-71.39%234.53%-154.01%

Earnings

Report DateMay 14, 2021Jul 30, 2021Nov 15, 2021Feb 7, 2022May 13, 2022Aug 12, 2022Nov 14, 2022Mar 3, 2023Apr 27, 2023Jul 28, 2023Oct 26, 2023Feb 1, 2024May 14, 2024Aug 13, 2024Nov 13, 2024Feb 5, 2025May 14, 2025Aug 12, 2025Nov 13, 2025Mar 13, 2026May 13, 2026Aug 10, 2026Oct 26, 2026
EPS Estimate--1045.292579.401280.08734.68105.87373.15124.85-19.16437.30-312.00-311.62-337.93-318.43-412.97-343.95-199.73-597.04-688.96-240.30-340.68-453.86
EPS Actual654.00688.001010.002387.15361.00598.00270.00360.00-186.00-208.00630.0035.00-179.00-148.00-290.00-80.00-95.00-210.00313.00-740.00-425.00-229.00-
Surprise---3.38%-7.45%-71.80%-18.60%155.03%-3.52%-248.98%-985.60%44.07%111.22%42.56%56.20%8.93%80.63%72.38%-5.14%152.43%-7.41%-76.86%32.78%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.89T
Enterprise Value2.52T
Trailing P/E0.00
Forward P/E46.51
Price / Sales4.38
Price / Book1.61
Revenue (TTM)659.27B
Gross Profit (TTM)93.53B
EBITDA-33.04B
Profit Margin-12.85%
Operating Margin-10.11%
Return on Equity-4.25%
Return on Assets-2.81%
Shares Outstanding78.46M
Shares Float25.61M
Beta0.88
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%